Venetoclax in children with relapsed AML

Estado	Tipo de Participantes	Rangos de Edad
Reclutando	No aportado	Adultos (18-64 años) , Adolescentes (12-17 años) , Niños (2-11 años) , Lactantes y preescolar (28 días - 23 meses) , Recién nacidos (0-27 días)
Género	**Fases**	**Participantes esperados**
Ambos	Fase III	48
Resultados	**Bajo nivel intervención**	**Enfermedad rara**
Sin resultados	No	Si
Cobertura geográfica	**Ámbitos del ensayo**	**Terapia avanzada**
Sin determinar	tratamiento, seguridad, eficacia, farmacocinética, farmacodinamica	NO

Información

Identificador
2023-510160-12-00 (CTIS)

Cod. Protocolo
ITCC-101/APAL2020D

Transicionado 2021-003212-11

Área terapéutica
Enfermedades [C] - Cáncer [C04]|

Enfermedad investigada
acute myeloid leukemia

Título Científico
A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML

Justificación

No aportado

Objetivo Principal

To assess if venetoclax combined with FLA+GO (fludarabine, high-dose cytarabine, and gemtuzumab ozogamicin) will improve overall survival of children with relapsed acute myeloid leukemia (AML) compared to FLA+GO.

Variables de Evaluación Primaria

The primary endpoint of the study is overall survival (OS). OS is defined as time from randomization until death of any cause.

Momentos temporales de evaluación primaria

No aportado

Objetivo Secundario

No aportado

Variables de Evaluación Secundaria

No aportado

Momentos temporales de evaluación secundaria

No aportado

Criterios de Inclusión

1. Patient must have the following: a. Children, adolescents, and young adults with acute myeloid leukemia without demonstrated FLT3/ITD mutation. Ideally, the status of the mutation needs to be proven in the current relapse. Nevertheless, patients with previous FLT3/ITD negative test from prior lines can be included based on local results in order to not delay the start of treatment. b. And patients must have AML which is either: - untreated second relapse, in patients who are sufficiently fit to undergo another round of intensive chemotherapy, or - untreated first relapse, in patients who cannot tolerate additional anthracycline containing chemotherapy per investigator discretion. 10. Patients must be off medications to treat or prevent either graft-versus- host disease post bone marrow transplant or organ rejection post- transplant for at least 14 days. 11. Cellular Therapy: 42 days after the completion of any type of

cellular therapy. 12. Adequate organ function . a.Adequate Renal Function defined as: Calculated eGFR (based on Schwartz formula) or radioisotope GFR 60ml/min/1.73 m2, OR A serum creatinine based on age/sex b.Adequate Liver Function defined as: Total or direct (conjugated) bilirubin 1.5xULN, AND Alkaline phosphatase 2.5xULN, AND SGPT (ALT) 2.5xULN o if higher transaminases outside these ranges (up to 5x ULN) are due to a radiographically identifiable leukemia infiltrate, the patient will remain eligible. Transaminase elevation up to 5x ULN is also allowed in case of steatosis on echography. c.Cardiac performance: Minimum cardiac function defined as: No history of congestive heart failure in need of medical treatment No pre-treatment diminished left ventricular function on echocardiography (FS <25% or EF <40%) No signs of congestive heart failure at presentation of relapse 13. Informed consent: Patient, parent or legal guardian must sign and date informed consent and pediatric assent (when required), prior to the initiation of screening or study specific procedures. 2. Patients must have a performance status corresponding to ECOG scores of 0, 1 or 2 (50% Lansky or Karnofsky score) 3. Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the minimum duration from prior anti-cancer directed therapy prior to enrolment (more details in the protocol). 4. Cytotoxic chemotherapy: Must not have received cytotoxic chemotherapy within 14 days prior to start of protocol treatment, except for corticosteroids, low dose cytarabine or hydroxyurea (see below) that can be given up to 24 hours prior to start of protocol treatment. 5. Antibodies: 21 days must have elapsed from infusion of last dose of an antibody-drug conjugate prior to start of protocol treatment. 6. Interleukins, Interferons and Cytokines : 21 days after the completion of interleukins, interferon or cytokines. 7. Hematopoietic growth factors: 14 days after the last dose of a long- acting growth factor or 7 days for short-acting growth factor prior to start of protocol treatment. 8. Radiation therapy (RT): Between 14 and 84 days depeding on the extent of radiation fields. 9. Stem Cell Infusions: 84 days since allogeneic bone marrow or stem cell transplant or boost infusion. No evidence of active graft versus host disease.

Criterios de Exclusión

1. Patients who in the opinion of the investigator may not be able to comply with the study requirements of the study, are not eligible.
10. Known hepatitis C virus (HCV), hepatitis B virus (HBV) (known positive hepatitis B virus (HBV) surface antigen (HBsAg) result) or human immunodeficiency virus (HIV) infection. Note: For the countries under EU CTR, these tests are required at screening. For other countries not under EU CTR, HCV, HBV, and HIV testing does not need to be conducted at screening unless it is required per local guidelines or local regulations.
11. Concomitant Medications - Patients who have received strong and moderate CYP3A inducers such as rifampin, carbamazepine, phenytoin, and St. John's wort within 7 days of the start of study treatment. - Patients who have consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or starfruit within 3 days of the start of study treatment. - Patients who are hypersensitive to the active substance or to any of the excipients listed in SPC.
12. Pregnancy or Breast-Feeding: - Patients who are pregnant or breast-feeding. - Patients of reproductive potential may not participate unless they have agreed to use a highly effective contraceptive method per CTFG guidelines for the duration of study therapy and at least 30 days after last dose of venetoclax, or 7 months after gemtuzumab ozogamicin treatment, or for 6 months after the completion of all study therapy , whichever is longer. - Male patients must use a condom during intercourse and agree not to father a child or donate sperm during therapy and for the duration of study therapy and at least 30 days after last dose of venetoclax or 4 months after last dose of gemtuzumab ozogamicin, 6 months from the last dose of cytarabine, or 90-days after last exposure to any other chemotherapy, whichever is longer.
13. Gemtuzumab ozogamicin should not be given: -to patients with history of veno-occlusive disease (VOD/SOS)/ Sinusoidal obstruction syndrome (SOS) grade 3 or 4 -to patients with CD33 negative leukemic blasts (determined at local lab). These patients are eligible for the study but will not be treated with gemtuzumab ozogamicin.
2. Patients with Down syndrome.
3. Patients with Acute promyelocytic leukemia (APL) or Juvenile myelomonocytic leukemia (JMML).
4. Patients with isolated CNS3 disease or symptomatic CNS3 disease.
5. Patients with malabsorption syndrome or any other condition that precludes enteral administration of venetoclax.
6. 1.6 Patients who are currently receiving an investigational drug other than those specified for this study (Venetoclax, Fludarabine, Cytarabine, GO and Azacitidine are considered investigational in this study in the countries under EU CTR. For other countries not under EU CTR, please refer to section 9).
7. Patients with Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known congenital bone

marrow failure syndrome.
8. Patients with known prior allergy to any of the medications used in protocol therapy.
9. Patients with documented active, uncontrolled infection at the time of study entry.

Calendario

(Última actualización: 20/04/2026)

Autorización	Inicio de Ensayo	Inclusión Primer Paciente	Interrumpido	Reiniciado
15/09/2022	31/01/2023	12/06/2023	No aportado	No aportado

Fin de reclutamiento	Fin prematuro (España)	Fin prematuro (Global)	Fin del ensayo en España	Fin del ensayo global
No aportado	No aportado	No aportado	No aportado	No aportado

Promotor

Prinses Maxima Centrum voor Kinderoncologie B.V. Netherlands

Heidelberglaan 25

Contact Person

Princess Máxima Center for Pediatric Oncology

+31889725206

PedAI-Venetoclax@prinsesmaximacentrum.nl

Monetary support: N/A

Tipo de promotor: No comercial

Ceim

CEIm Hospital Universitari Vall d Hebron

Passeig de la Vall d.Hebron, 119-129 - Edificio Materno-Infantil, planta 13 08035 Barcelona

ceic@vhir.org

934894010

Centros

Activo (10/11/2023)

FUNDACIO HOSPITAL SANT JOAN DE DEU

Martorell

BARCELONA

Hematology

No iniciado (--/--/----)

Hospital Infantil Universitario Nino Jesus

Madrid

MADRID

Paediatric Haemato-Oncology Service

Activo (31/01/2023)

HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESUS

Madrid

MADRID

Paediatric Haemato-Oncology

Activo (31/10/2023)

HOSPITAL UNIVERSITARI VALL D'HEBRON

Barcelona

BARCELONA

Pediatric Oncology and Hematology

Activo (17/02/2023)

HOSPITAL UNIVERSITARIO Y POLITECNICO LA FE

València

VALENCIA

Unidad de Oncología y Transplante Pediátrico

No iniciado (--/--/----)

Hospital Universitario Y Politecnico La Fe

Valencia

VALENCIA

Unidad de Oncologia y trasplante pediatrico

No iniciado (--/--/----)

Sant Joan De Deu Barcelona Hospital

Esplugues De Llobregat

BARCELONA

Hematology

Medicamentos

Venetoclax
ORAL SUSPENSION
ORAL USE

-

Principios Activos: N/A

Experimental

-
-
INTRAVENOUS USE

Código ATC: L01FX02 - GEMTUZUMAB OZOGAMICINA
Principios Activos: N/A

Huérfano Experimental

-
-
SUBCUTANEOUS USE

Código ATC: L01BC07 - AZACITIDINA
Principios Activos: N/A

Experimental

-
-
INTRAVENOUS

Código ATC: L01BB05 - FLUDARABINA
Principios Activos: N/A

Experimental

-
-
INTRAVENOUS USE

Código ATC: L01BC01 - CITARABINA
Principios Activos: N/A

Experimental

Venetoclax
ORAL SUSPENSION
ORAL USE

-

Principios Activos: N/A

Experimental

Venetoclax
FILM-COATED TABLET
ORAL USE

-

Principios Activos: N/A

Experimental

Venetoclax
ORAL SUSPENSION
ORAL USE

-

Principios Activos: N/A

Experimental

Venetoclax
FILM-COATED TABLET
ORAL USE

-

Principios Activos: N/A

Experimental

Venetoclax
ORAL SUSPENSION
ORAL USE

-

Principios Activos: N/A

Experimental

Venetoclax
ORAL SUSPENSION
ORAL USE

-

Principios Activos: N/A

Experimental

Venetoclax
FILM-COATED TABLET
ORAL USE

-

Principios Activos: N/A

Experimental

Sin resultados

Venetoclax in children with relapsed AML

State	Type of participants	Age Ranges
Recruiting	Not provided	Adults (18-64 years) , Teens (12-17 years) , Children (2-11 years) , Infants and preschool (28 days - 23 months) , Newborn infants (0-27 days)
Gender	**Phases**	**Expected Participants**
Both	Phase III	48
Results	**Low level of intervention**	**Rare disease**
No results	No	Yes
Geographic coverage	**Areas of the study**	**Advanced therapy**
Undetermined	treatment, safety, effectiveness, pharmacokinetics, pharmacodynamics	NO

Information

Identifier
2023-510160-12-00 (CTIS)

Protocol Code
ITCC-101/APAL2020D

Transitioned 2021-003212-11

Therapeutic area
Diseases [C] - Cancer [C04]|

Investigated Disease
acute myeloid leukemia

Scientific Title
A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML

Rationale

Not provided

Main Objective

To assess if venetoclax combined with FLA+GO (fludarabine, high-dose cytarabine, and gemtuzumab ozogamicin) will improve overall survival of children with relapsed acute myeloid leukemia (AML) compared to FLA+GO.

Primary Endpoints

The primary endpoint of the study is overall survival (OS). OS is defined as time from randomization until death of any cause.

Temporary moments of secondary assessment

Not provided

Secondary Objective

Not provided

Secondary Endpoints

Not provided

Temporary moments of secondary assessment

Not provided

Inclusion criteria

1. Patient must have the following: a. Children, adolescents, and young adults with acute myeloid leukemia without demonstrated FLT3/ITD mutation. Ideally, the status of the mutation needs to be proven in the current relapse. Nevertheless, patients with previous FLT3/ITD negative test from prior lines can be included based on local results in order to not delay the start of treatment. b. And patients must have AML which is either: - untreated second relapse, in patients who are sufficiently fit to undergo another round of intensive chemotherapy, or - untreated first relapse, in patients who cannot tolerate additional anthracycline containing chemotherapy per investigator discretion. 10. Patients must be off medications to treat or prevent either graft-versus- host disease post bone marrow transplant or organ rejection post- transplant for at least 14 days. 11. Cellular Therapy: 42 days after the completion of any type of

cellular therapy. 12. Adequate organ function . a.Adequate Renal Function defined as: Calculated eGFR (based on Schwartz formula) or radioisotope GFR 60ml/min/1.73 m2, OR A serum creatinine based on age/sex b.Adequate Liver Function defined as: Total or direct (conjugated) bilirubin 1.5xULN, AND Alkaline phosphatase 2.5xULN, AND SGPT (ALT) 2.5xULN o if higher transaminases outside these ranges (up to 5x ULN) are due to a radiographically identifiable leukemia infiltrate, the patient will remain eligible. Transaminase elevation up to 5x ULN is also allowed in case of steatosis on echography. c.Cardiac performance: Minimum cardiac function defined as: No history of congestive heart failure in need of medical treatment No pre-treatment diminished left ventricular function on echocardiography (FS <25% or EF <40%) No signs of congestive heart failure at presentation of relapse 13. Informed consent: Patient, parent or legal guardian must sign and date informed consent and pediatric assent (when required), prior to the initiation of screening or study specific procedures. 2. Patients must have a performance status corresponding to ECOG scores of 0, 1 or 2 (50% Lansky or Karnofsky score) 3. Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the minimum duration from prior anti-cancer directed therapy prior to enrolment (more details in the protocol). 4. Cytotoxic chemotherapy: Must not have received cytotoxic chemotherapy within 14 days prior to start of protocol treatment, except for corticosteroids, low dose cytarabine or hydroxyurea (see below) that can be given up to 24 hours prior to start of protocol treatment. 5. Antibodies: 21 days must have elapsed from infusion of last dose of an antibody-drug conjugate prior to start of protocol treatment. 6. Interleukins, Interferons and Cytokines : 21 days after the completion of interleukins, interferon or cytokines. 7. Hematopoietic growth factors: 14 days after the last dose of a long- acting growth factor or 7 days for short-acting growth factor prior to start of protocol treatment. 8. Radiation therapy (RT): Between 14 and 84 days depeding on the extent of radiation fields. 9. Stem Cell Infusions: 84 days since allogeneic bone marrow or stem cell transplant or boost infusion. No evidence of active graft versus host disease.

Exclusion criteria

1. Patients who in the opinion of the investigator may not be able to comply with the study requirements of the study, are not eligible.
10. Known hepatitis C virus (HCV), hepatitis B virus (HBV) (known positive hepatitis B virus (HBV) surface antigen (HBsAg) result) or human immunodeficiency virus (HIV) infection. Note: For the countries under EU CTR, these tests are required at screening. For other countries not under EU CTR, HCV, HBV, and HIV testing does not need to be conducted at screening unless it is required per local guidelines or local regulations.
11. Concomitant Medications - Patients who have received strong and moderate CYP3A inducers such as rifampin, carbamazepine, phenytoin, and St. John's wort within 7 days of the start of study treatment. - Patients who have consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or starfruit within 3 days of the start of study treatment. - Patients who are hypersensitive to the active substance or to any of the excipients listed in SPC.
12. Pregnancy or Breast-Feeding: - Patients who are pregnant or breast-feeding. - Patients of reproductive potential may not participate unless they have agreed to use a highly effective contraceptive method per CTFG guidelines for the duration of study therapy and at least 30 days after last dose of venetoclax, or 7 months after gemtuzumab ozogamicin treatment, or for 6 months after the completion of all study therapy , whichever is longer. - Male patients must use a condom during intercourse and agree not to father a child or donate sperm during therapy and for the duration of study therapy and at least 30 days after last dose of venetoclax or 4 months after last dose of gemtuzumab ozogamicin, 6 months from the last dose of cytarabine, or 90-days after last exposure to any other chemotherapy, whichever is longer.
13. Gemtuzumab ozogamicin should not be given: -to patients with history of veno-occlusive disease (VOD/SOS)/ Sinusoidal obstruction syndrome (SOS) grade 3 or 4 -to patients with CD33 negative leukemic blasts (determined at local lab). These patients are eligible for the study but will not be treated with gemtuzumab ozogamicin.
2. Patients with Down syndrome.
3. Patients with Acute promyelocytic leukemia (APL) or Juvenile myelomonocytic leukemia (JMML).
4. Patients with isolated CNS3 disease or symptomatic CNS3 disease.
5. Patients with malabsorption syndrome or any other condition that precludes enteral administration of venetoclax.
6. 1.6 Patients who are currently receiving an investigational drug other than those specified for this study (Venetoclax, Fludarabine, Cytarabine, GO and Azacitidine are considered investigational in this study in the countries under EU CTR. For other countries not under EU CTR, please refer to section 9).
7. Patients with Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known congenital bone

marrow failure syndrome.
8. Patients with known prior allergy to any of the medications used in protocol therapy.
9. Patients with documented active, uncontrolled infection at the time of study entry.

Calendar

(Last Update: 20/04/2026)

Authorization	Start of Trial	First patient inclusion	Halted	Restarted
15/09/2022	31/01/2023	12/06/2023	Not aported	Not aported

End of recruitment	Premature end (Spain)	Premature End (Global)	Trial end (Spain)	Trial end (Global)
Not aported	Not aported	Not aported	Not aported	Not aported

Sponsor

Prinses Maxima Centrum voor Kinderoncologie B.V. Netherlands

Heidelberglaan 25

Contact Person

Princess Máxima Center for Pediatric Oncology

+31889725206

PedAI-Venetoclax@prinsesmaximacentrum.nl

Monetary support: N/A

Sponsor type: No commercial

Ceim

CEIm Hospital Universitari Vall d Hebron

Passeig de la Vall d.Hebron, 119-129 - Edificio Materno-Infantil, planta 13 08035 Barcelona

ceic@vhir.org

934894010

Sites

Active (10/11/2023)

FUNDACIO HOSPITAL SANT JOAN DE DEU

Martorell

BARCELONA

Hematology

not initialized (--/--/----)

Hospital Infantil Universitario Nino Jesus

Madrid

MADRID

Paediatric Haemato-Oncology Service

Active (31/01/2023)

HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESUS

Madrid

MADRID

Paediatric Haemato-Oncology

Active (31/10/2023)

HOSPITAL UNIVERSITARI VALL D'HEBRON

Barcelona

BARCELONA

Pediatric Oncology and Hematology

Active (17/02/2023)

HOSPITAL UNIVERSITARIO Y POLITECNICO LA FE

València

VALENCIA

Unidad de Oncología y Transplante Pediátrico

not initialized (--/--/----)

Hospital Universitario Y Politecnico La Fe

Valencia

VALENCIA

Unidad de Oncologia y trasplante pediatrico

not initialized (--/--/----)

Sant Joan De Deu Barcelona Hospital

Esplugues De Llobregat

BARCELONA

Hematology

Medication

Venetoclax
ORAL SUSPENSION
ORAL USE

-

Active Principles: N/A

Experimental

-
-
INTRAVENOUS USE

ATC code: L01FX02 - GEMTUZUMAB OZOGAMICINA
Active Principles: N/A

Orphan Experimental

-
-
SUBCUTANEOUS USE

ATC code: L01BC07 - AZACITIDINA
Active Principles: N/A

Experimental

-
-
INTRAVENOUS

ATC code: L01BB05 - FLUDARABINA
Active Principles: N/A

Experimental

-
-
INTRAVENOUS USE

ATC code: L01BC01 - CITARABINA
Active Principles: N/A

Experimental

Venetoclax
ORAL SUSPENSION
ORAL USE

-

Active Principles: N/A

Experimental

Venetoclax
FILM-COATED TABLET
ORAL USE

-

Active Principles: N/A

Experimental

Venetoclax
ORAL SUSPENSION
ORAL USE

-

Active Principles: N/A

Experimental

Venetoclax
FILM-COATED TABLET
ORAL USE

-

Active Principles: N/A

Experimental

Venetoclax
ORAL SUSPENSION
ORAL USE

-

Active Principles: N/A

Experimental

Venetoclax
ORAL SUSPENSION
ORAL USE

-

Active Principles: N/A

Experimental

Venetoclax
FILM-COATED TABLET
ORAL USE

-

Active Principles: N/A

Experimental

No results